Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LevoHeartShock: Early Levosimendan in Cardiogenic Shock
2019-001563-74Phase 3Active
- Sponsor
- CHRU Nancy
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiogenic shock comparing Levosimendan + conventional inotropes with Placebo + conventional inotropes (2 arms). Primary endpoint: Primary composite endpoint at day 30. Started Jun 2020; status: active.
02
Drugs
levosimendan
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on 2019-001563-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001563-74.